Radiotherapy for Renal Cell Carcinoma - Renaissance of An Overlooked Approach - Enduring

Renal cell carcinoma (RCC) has previously been thought of as a radioresistant disease. Until recently, the application of radiation treatment has been largely palliative. Previously there was a paucity of therapy available for RCC. Now there are novel modalities such as stereotactic body radiation therapy (SBRT), which makes it easier to treat. It is essential to stay abreast of such important updates, in order to achieve and deliver appropriate care, in an effort to improve patient quality of life. 

Target Audience

Medical oncologists, urologists and radiation oncologists.

Learning Objectives

  • Outline the appropriate settings in which to use radiotherapy in renal cell carcinoma (RCC).
  • Review the definitions of oligoprogressive disease.
  • Examine which systemic therapy strategies best synergize with radiotherapy in RCC.
  • Discuss emerging trials that will shape the use of RCC and SBRT in concert.
  • Discuss possible barriers and biases which may impact patient care (i.e., race, ethnicity, language, gender identity/orientation, age, socioeconomic status, attitudes, feelings, or other characteristics).
Activity summary
Available credit: 
  • 1.00 AMA PRA Category 1 Credit™
    City of Hope is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
    City of Hope designates this Radiotherapy for Renal Cell Carcinoma - Renaissance of An Overlooked Approach - Enduring for a maximum of 1.00 AMA PRA Category 1 Credit™ requirements. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
  • 1.00 Attendance
Activity opens: 
04/07/2022
Activity expires: 
04/07/2023
Internet
United States

This activity has been planned and implemented in strict compliance with the accreditation requirements, standards, and policies of the ACCME. City of Hope takes responsibility for the content, quality and scientific integrity of this CME activity.

As an accredited CME provider City of Hope requires everyone who is in a position to control the content of an educational activity to disclose all relevant financial relationships with any commercial interest. The ACCME defines "relevant financial relationships" as financial relationships in any amount, occurring within the past 24 months, including financial relationships of a spouse that could create a conflict of interest. Any potential conflicts relative to the previous disclosure have been resolved.

Presenter: Dr. Shankar Siva has indicated he receives Grant/Research Support from RefleXion Medical, and Varian Industries; is On the Speakers Bureau for AstraZeneca.

City of Hope further encourages faculty/ authors to identify investigational products or off-label uses of products regulated by the U.S. Food and Drug Administration, at first mention and where appropriate in the content.

The information and opinions presented in this activity do not constitute medical or legal advice. Health care providers must exercise their own professional judgment in their clinical practice, and when confronted with the issues discussed herein, should not substitute this curriculum for the advice of legal counsel or application of sound ethical principles.

 Radiotherapy for Renal Cell Carcinoma - Renaissance of An Overlooked Approach - Enduring has received no commercial support.

ACCREDITATION STATEMENT: City of Hope is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

CREDIT DESIGNATION: City of Hope designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity. 

The following credit type(s) are being offered for this course:

•  AMA PRA Category 1 Credit™  1.0

The following may apply AMA PRA Category 1 Credit™ for license renewal:

Registered Nurses: Nurses may report up to 1.0 credit hours toward the continuing education requirements for license renewal by their state Board of Registered Nurses (BRN). AMA PRA Category 1 Credit™ may be noted on the license renewal application in lieu of a BRN provider number.

Physician Assistants: The National Commission on Certification of Physicians Assistants states that AMA PRA Category 1 Credit™ accredited courses are acceptable for CME requirements for recertification.
 

Available Credit

  • 1.00 AMA PRA Category 1 Credit™
    City of Hope is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
    City of Hope designates this Radiotherapy for Renal Cell Carcinoma - Renaissance of An Overlooked Approach - Enduring for a maximum of 1.00 AMA PRA Category 1 Credit™ requirements. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
  • 1.00 Attendance
Please login or register to take this activity.

You must be logged in to access this Enduring. 

If you are a New User, please create an account first, by clicking on "Register". 

Once Logged in: 

Click on "Start Activity" to access the educational content for this Enduring activity.

Required Hardware/software

Current version of Edge, Firefox, Safari, or Chrome.